Thrive Acquisition Corporation Class A ordinary shares
THAC
THAC was delisted on the 25th of January, 2023.
0 hedge funds and large institutions have $0 invested in Thrive Acquisition Corporation Class A ordinary shares in 2023 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 48 closing their positions.
100% less funds holding
Funds holding: 48 → 0 (-48)
100% less capital invested
Capital invested by funds: $161M → $0 (-$161M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 48
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Saba Capital Management
New York
|
-$16M |
| 2 |
D.E. Shaw & Co
New York
|
-$14.8M |
| 3 |
FTCM
First Trust Capital Management
Chicago,
Illinois
|
-$13.8M |
| 4 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
-$11.3M |
| 5 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
-$10.3M |
THAC Hedge Fund Activity: Q1 2023 in Review
0 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Thrive Acquisition Corporation Class A ordinary shares (THAC) for Q1 2023, worth a combined $0 — down 100% from $161M a quarter earlier.
Sellers outnumbered buyers: 48 funds closed out of THAC and 0 opened new positions — a net loss of 48 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Saba Capital Management, exiting entirely with an estimated $16M sold.
- 0 institutional investors held Thrive Acquisition Corporation Class A ordinary shares (THAC) as of Q1 2023, down from 48 in Q4 2022.
- Funds reported $0 of Thrive Acquisition Corporation Class A ordinary shares stock for Q1 2023, down 100% quarter-over-quarter.
- 0 funds opened new Thrive Acquisition Corporation Class A ordinary shares positions in Q1 2023 and 48 closed out, a net change of -48 holders.
- The largest Thrive Acquisition Corporation Class A ordinary shares seller in Q1 2023 was Saba Capital Management, an estimated $16M sold.
Based on aggregated 13F filings for Q1 2023.